In today’s briefing:
- Hangzhou Tigermed Consulting (3347.HK/300347.CH) 2022H1 – The Time Bomb Is Ticking
- Boston Scientific: Major Drivers
- Gilead Sciences: The MiroBio Acquisition & Other Drivers
- Oneness Biotech (4743 TT): Positive Clinical Trial Progress Is Pushing Stock Prices to Higher Highs
- Teladoc Inc: Major Drivers
Hangzhou Tigermed Consulting (3347.HK/300347.CH) 2022H1 – The Time Bomb Is Ticking
- Tigermed had high revenue growth in 2022H1 but with a YoY decrease in net profit attributable to the owners of the Company, mainly due to poor performance of investment business.
- Tigermed’s investment business is like a “time bomb” that would detonate in the future. Its “CRO+PE/VC business model” would trap its performance in a vicious circle due to unfriendly macro.
- We are conservative about Tigermed’s outlook and performance. Tigermed is difficult to achieve the V-shaped rebound. So we recommend investors to offload, or just do some short term trade.
Boston Scientific: Major Drivers
- Boston Scientific’s innovation portfolio, commercial execution, clinical data, and strategic tuck-in M&A supported its solid second-quarter results where the company delivered an all-around beat.
- Furthermore, their Diagnostics business performed well during the quarter because of the Preventice portfolio and implantable cardiac LUX-Dx.
- Despite the macroeconomic difficulties Boston continues to be well-positioned for a decent 2022 ahead given their category leadership strategy, commercial execution, and robust portfolio.
Gilead Sciences: The MiroBio Acquisition & Other Drivers
- Gilead had a very robust second quarter with total product sales of $5.7 billion, up 7% year over year, excluding Veklury.
- The company managed to deliver an all-around beat powered by HIV, cell therapy, and Trodelvy, partially offset by HCV.
- Sequentially, total product sales excluding Veklury increased by 14%, driven by seasonal pricing and inventory dynamics, especially in their HIV business, and increased demand across the whole portfolio.
Oneness Biotech (4743 TT): Positive Clinical Trial Progress Is Pushing Stock Prices to Higher Highs
- Oneness Biotech (4743 TT) is showing steady progress in its R&D pipeline. The company submitted IND application to FDA for phase 1 trial of SNS812 for the treatment of COVID-19.
- SNS812 is a first-in-class broad-spectrum siRNA-based new drug against SARS-CoV-2 variants covering 99.8% of current variants and shown picomolar inhibition of dominant ones, including Alpha, Delta, Gamma, Epsilon, and Omicron.
- The health authorities in Singapore, Malaysia, the Philippines, and Vietnam have accepted the NDA application of Fespixon, which has been commercialized in Taiwan last year for diabetes foot ulcer.
Teladoc Inc: Major Drivers
- Teladoc delivered a mixed result and managed to surpass Wall Street expectations on the revenue front but its losses were more than market expectations.
- The management continues its efforts towards creating solutions that change how customers engage with the healthcare system.
- This growth builds on the company’s current relationship in chronic care and will give plan members access to a wide range of integrated primary and chronic care options.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
